Mylan Fact Sheet

Our Mission
At Mylan, we are committed
to setting new standards in
healthcare. Working together
around the world to provide
7 billion people access to high
quality medicine, we:
Innovate to satisfy unmet needs
Make reliability and service
excellence a habit
Do whats right, not whats easy

Mylan is one of the worlds leading global pharmaceutical companies.

Our medicines include generic, brand name and over-the-counter
products in a variety of dosage forms and therapeutic categories,
such as difficult-to-manufacture injectables, transdermal patches,
topicals and HIV/AIDS antiretroviral (ARV) therapies. The company
has innovative research and development capabilities and is one of
the worlds largest active pharmaceutical ingredient (API) manufacturers.
Mylan applies one global quality standard to all of our medications
regardless of where they are produced.

Fast Facts

2015 Revenue: $9.45 billion*

Ticker: NASDAQ, TASE: MYL

Global workforce: more than 40,000

Products: a global market portfolio of more than 2,700 separate products
Product submissions: more than 3,400 new product submissions pending
regulatory approval around the world*
Global presence: sell products in more than 165 countries and territories
U.S. presence: one out of every 13 prescriptions dispensed in the U.S. brand
name or generic is a Mylan product
Manufacturing presence: operate more than 50 facilities around the globe
 &D capabilities: include an extensive range of dosage forms and delivery
R
systems, including oral solid doses, transdermal patches, injectables, respiratory
inhalants, dermatologics, topicals, soft gel capsules, nasal sprays, solutions,
suspensions, ophthalmics, ARVs and APIs
ARV access: approximately 50% of people living with HIV/AIDS in the
developing world who are receiving treatment depend on a Mylan product
Notable: member of S&P 500

*Not inclusive of Renaissance/Meda

Impact the future through

passionate global leadership

Creating better health for a

better world. Thats what
inspires Mylans mission of
providing quality healthcare
to the worlds 7 billion people,
one person at a time.

OUR VALUES INNOVATION | INTEGRITY | RELIABILITY | SERVICE | TEAMWORK

NORTH AMERICA
n Caguas, Puerto Rico
l Decatur, Illinois
D n Morgantown, West Virginia
n Rockford, Illinois
D l Saint-Hubert, Quebec
D l San Antonio, Texas (3)
D l St. Albans, Vermont
l Sugar Land, Texas

D

n

n

n
D n l
Ds

n

l

n

D

D

D

n

s

SOUTH AMERICA
s Campos, Brazil (2)

n Oral Solid Doses: 23

l Complex Products: 9

Our Evolution
1961
Founded by Milan Mike Puskar and
Don Panoz in White Sulphur Springs,
West Virginia, U.S.

1973
Became a publicly traded company

1984
Received our first branded product approval

2002

EUROPE
Cambridge, U.K.
Chtillon, France
Cologne, Germany
Confienza, Italy
Dublin, Ireland (2)
Galway, Ireland
Komarom, Hungary
Merignac, France
Meyzieu, France
Monza, Italy
Radebeul, Germany
Sandwich, U.K.
Troisdorf, Germany
Warsaw, Poland

s Injectables: 11

Went global with the acquisitions

of Matrix and Merck Generics

JAPAN

n Aurangabad
D s Bangalore (5)
n Daman
s Hosur
D u Hyderabad (4)
n Indore
n Jadcherla
n Jaggaiahpet
u Mumbai
n Nashik
n Sarigam (2)
s u Vizag (4)

n Katsuyama
D n Kawagoe
AUSTRALIA
n Carole Park, Queensland

u Active Pharmaceutical Ingredients: 9

D Research and Development: 14

Powerful Global Commercial Presence*

U.S.

Europe

India

Japan

One in 13 prescriptions in the U.S.,

brand name or generic, is filled with a
Mylan product
Mylan represents 20% of the
Hepatitis C market share in India

Canada

Mylan products are sold in eight out of 10

pharmacies in Canada

Generated more than $1 billion

in revenue for the first time

2007

INDIA

D n Ahmedabad

Mylan holds leadership positions in several

key European markets, including France,
Italy, the Netherlands, Portugal and the U.K.
Mylan has been the fastest grower in the Japan
generics market for the last three years

Australia

Mylan is the No. 1 supplier by volume to

Australias national pharmaceuticals program
* Not inclusive of Renaissance/Meda

Excluding authorized generics

Leadership

2012
Helped champion the U.S. Food and Drug
Administration Safety and Innovation Act

Robert J. Coury

Heather Bresch

Rajiv Malik

Chairman

Chief Executive Officer

President

Ken Parks

Tony Mauro

Chief Financial Officer

Chief Commercial Officer

2013
Acquired Agila Specialties and
became a global injectables leader

2015
Acquired Abbotts non-U.S. developed markets
specialty and branded generics business
Acquired certain businesses from Famy Care
to become a global womens healthcare leader

2016
Acquired topicals-focused specialty and
generics business from Renaissance
Acquired Meda, a leading international
specialty pharmaceutical company

Stay Connected
2016 Mylan N.V. All rights reserved. (July 2016)
The Mylan logo is a registered trademark of Mylan Inc.

Media Relations:
+1.724.514.1968
Communications@mylan.com
Investor Relations:
+1.724.514.1813
InvestorRelations@mylan.com

Mylan.com

@MylanNews
@MylanCareers